A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation

Randomized Controlled Trial

. 2010 Sep;22(9):991-8, e255.

doi: 10.1111/j.1365-2982.2010.01533.x. Epub 2010 Jun 7.

Affiliations

PMID: 20529205
DOI: 10.1111/j.1365-2982.2010.01533.x

Randomized Controlled Trial

S Müller-Lissner et al. Neurogastroenterol Motil. 2010 Sep.

Abstract

Background: Constipation affects up to 50% of the elderly; this study evaluates the efficacy, safety, and tolerability of the selective 5-HT(4) agonist prucalopride in chronically constipated elderly patients.

Methods: Three hundred chronic constipation patients aged >or=65 years were randomized to prucalopride (1, 2, or 4 mg once daily) or placebo for 4 weeks. The primary endpoint was the percentage of patients with >or=3 spontaneous complete bowel movements (SCBM) per week. Secondary endpoints included the percentage with an increase of >or=1 SCBM per week, BM frequency, constipation-related symptoms, quality of life (QoL), safety, and tolerability.

Key results: More patients achieved >or=3 SCBM per week with prucalopride than with placebo. This difference was largest and significant during the first week of 4 mg prucalopride (P <or= 0.05). Significantly more patients in each prucalopride group achieved an increase of >or=1 SCBM per week from baseline vs placebo (e.g. 60% with 1 mg prucalopride vs 34% with placebo at week 4; P <or= 0.05). More patients had improvement in PAC-QOL satisfaction score of >or=1 with 1 mg prucalopride than with placebo (P <or= 0.05); the same was true for PAC-SYM stool symptoms (1 and 4 mg prucalopride; P <or= 0.05). Treatment-emergent adverse events were similar between groups: the most frequently reported with prucalopride were headache and gastrointestinal events. There were no clinically significant differences between prucalopride and placebo for vital signs, laboratory assessments, or ECG variables.

Conclusions & inferences: Prucalopride, in the dose-range tested (1-4 mg once daily), has beneficial effects on bowel movements, symptoms, and QoL, and is safe and well-tolerated in elderly patients with chronic constipation.

Trial registration: ClinicalTrials.gov NCT00487422.

PubMed Disclaimer

Cited by

Patient considerations in the management of chronic constipation: focus on prucalopride.
Shin A. Shin A. Patient Prefer Adherence. 2016 Jul 28;10:1373-84. doi: 10.2147/PPA.S92550. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27528801 Free PMC article. Review.
Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised Edition.
Shin JE, Jung HK, Lee TH, Jo Y, Lee H, Song KH, Hong SN, Lim HC, Lee SJ, Chung SS, Lee JS, Rhee PL, Lee KJ, Choi SC, Shin ES; Clinical Management Guideline Group under the Korean Society of Neurogastroenterology and Motility. Shin JE, et al. J Neurogastroenterol Motil. 2016 Jul 30;22(3):383-411. doi: 10.5056/jnm15185. J Neurogastroenterol Motil. 2016. PMID: 27226437 Free PMC article. Review.
Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies.
Derakhchan K, Lou Z, Wang H, Baughman R. Derakhchan K, et al. Drugs Context. 2023 Feb 27;12:2022-6-1. doi: 10.7573/dic.2022-6-1. eCollection 2023. Drugs Context. 2023. PMID: 36876155 Free PMC article.
An update on prucalopride in the treatment of chronic constipation.
Omer A, Quigley EMM. Omer A, et al. Therap Adv Gastroenterol. 2017 Nov;10(11):877-887. doi: 10.1177/1756283X17734809. Epub 2017 Oct 16. Therap Adv Gastroenterol. 2017. PMID: 29147138 Free PMC article. Review.
Novel pharmacological therapies for management of chronic constipation.
Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J. Gonzalez-Martinez MA, et al. J Clin Gastroenterol. 2014 Jan;48(1):21-8. doi: 10.1097/01.mcg.0000436440.05887.02. J Clin Gastroenterol. 2014. PMID: 24172177 Free PMC article. Review.

A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation - PubMed (original) (raw)